These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26116591)

  • 1. Neutrophil-Lymphocyte Ratio (NLR) Could Be Better Predictor than C-reactive Protein (CRP) for Liver Fibrosis in Non-alcoholic Steatohepatitis(NASH).
    Yilmaz H; Yalcin KS; Namuslu M; Celik HT; Sozen M; Inan O; Nadir I; Turkay C; Akcay A; Kosar A
    Ann Clin Lab Sci; 2015; 45(3):278-86. PubMed ID: 26116591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease.
    Khoury T; Mari A; Nseir W; Kadah A; Sbeit W; Mahamid M
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1110-1115. PubMed ID: 30888972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease.
    WenYi J; Ting Q; PiaoPiao Y; JinMing W
    Turk J Gastroenterol; 2022 Jan; 33(1):53-61. PubMed ID: 35040788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review.
    Peng Y; Li Y; He Y; Wei Q; Xie Q; Zhang L; Xia Y; Zhou X; Zhang L; Feng X; Chen K; Chen S; Chen W; Long Q; Chai J
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):503-513. PubMed ID: 29629626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis.
    Şen İ; Dumlu Ş
    Turk J Gastroenterol; 2024 Jul; 35(7):568-576. PubMed ID: 39128054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease.
    Kara M; Dogru T; Genc H; Sertoglu E; Celebi G; Gurel H; Kayadibi H; Cicek AF; Ercin CN; Sonmez A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1144-8. PubMed ID: 26062078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
    Cengiz M; Candır BA; Yılmaz G; Akyol G; Ozenirler S
    World J Gastroenterol; 2013 Nov; 19(42):7412-8. PubMed ID: 24259972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Role of Neutrophil to Lymphocyte Ratio in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Shavakhi M; Nourigheimasi S; Dioso E; Goutnik M; Lucke-Wold B; Khanzadeh S; Heidari F
    Can J Gastroenterol Hepatol; 2022; 2022():1554079. PubMed ID: 37601979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
    Alkhouri N; Morris-Stiff G; Campbell C; Lopez R; Tamimi TA; Yerian L; Zein NN; Feldstein AE
    Liver Int; 2012 Feb; 32(2):297-302. PubMed ID: 22097893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales.
    Michalak A; Cichoż-Lach H; Guz M; Kozicka J; Cybulski M; Jeleniewicz W; Stepulak A
    World J Gastroenterol; 2020 Dec; 26(47):7538-7549. PubMed ID: 33384553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018.
    Liu CF; Chien LW
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
    PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.